Deep Science Venture Studio.

We identify top scientists and entrepreneurs in Latin America and the USA, partnering with them to create innovative startups based on groundbreaking innovations. Our experienced management and technical teams guide these ventures, combining scientific expertise with strategic business acumen to develop successful enterprises.

Focus &

Expertise

At Securitas Biosciences, we bridge the gap between cutting-edge scientific research and practical, real-world applications. Our mission is to transform groundbreaking biotech discoveries into viable, market-ready solutions that address the world’s most pressing challenges. We strive to lead in startup creation through a pioneering approach that emphasizes scientific excellence, diversity, and inclusion. Our vision is to cultivate a thriving biotech ecosystem where innovation flourishes, driving forward advancements in medical and biotechnological science to benefit communities globally.

Strategic

Areas

Regenerative Medicine

Regenerative Medicine

Sinthetic Biology

Synthetic
Biology

NanoBioTechnology

NanoBio-Technology

Precision Medicine

Precision
Medicine

Small Molecule Development

Small Molecule Development

Regenerative Medicine

We focus on developing bioactive compounds and therapeutic agents that stimulate tissue growth and regeneration, both in vivo (within the body) and ex vivo (outside the body in controlled environments). These innovative treatments leverage the body's innate healing mechanisms to restore function and repair damaged or degenerated tissues. By harnessing cellular processes such as stem cell activation, extracellular matrix production, and growth factor modulation, regenerative medicine holds the potential to treat a wide range of conditions, from chronic degenerative diseases to acute injuries, offering transformative solutions that go beyond symptom management to address the root causes of tissue dysfunction.

Synthetic Biology

Our Synthetic Biology area focuses on re-designing and engineering biological systems to create innovative products across various industries. By utilizing advanced genetic tools and techniques, we develop organisms with novel capabilities that can produce valuable natural compounds or bio-based products. This approach enables the creation of sustainable solutions in areas such as biomanufacturing, pharmaceuticals, and agriculture, driving advancements in fields like bio-based drug development, industrial biotechnology, and environmental applications. Our work in synthetic biology is at the forefront of transforming scientific discoveries into scalable, commercially viable products with real-world impact.

NanoBioTechnology

Our NanoBiotechnology division focuses on developing advanced technologies that combine nanotechnology and biotechnology to create innovative therapeutic solutions. This includes the design and implementation of delivery systems for both small molecules and biologics, improving precision and effectiveness in targeted drug delivery. We also specialize in the development of viral vectors for cutting-edge treatments such as gene therapy, oncolytics, and vaccines, as well as Extracellular Vesicles (EV)-based therapies, which leverage natural vesicle systems for therapeutic applications. Additionally, this division is pioneering the creation of biopolymers with therapeutic potential, offering versatile applications in tissue engineering and regenerative medicine.

Precision Medicine

Our Precision Medicine division is focused on developing cutting-edge products and services that personalize healthcare. A key area of our work involves the creation of molecular signatures for the early detection and prediction of diseases that are difficult to diagnose in their early stages. We also design and validate companion diagnostic tests to guide the use of existing therapies, ensuring that treatments are tailored to the individual patient’s genetic profile. Additionally, our division develops and scales molecular tests for both common and rare diseases, providing clinicians with accurate and actionable data to improve patient outcomes.

Small Molecule Development

Our Small Molecule Development division is dedicated to discovering and optimizing new drug candidates using an integrated approach. We utilize computational techniques such as Artificial Intelligence (AI), Machine learning (ML), and Molecular Dynamics (MD) to accelerate the discovery and optimization of novel therapeutics. This is complemented by medicinal chemistry, including organic synthesis and molecular characterization, to refine and validate promising candidates. Our expertise extends to formulation development, ensuring that new compounds are optimized for clinical application. Additionally, we employ advanced biochemical and biophysical tools to study interactions between small molecules and biological targets, facilitating the development of highly effective and targeted therapies. This comprehensive process allows us to create innovative solutions for a wide range of diseases.

Companies

and Ventures

The companies we build are disruptive on a global scale. We validate the science and the market supporting each opportunity. In alliance with renowned research, medical, and manufacturing institutions in South America, we are setting the stage to become a LatAm biotech reference.

Securitas Biosciences Group is a Venture Studio focused on life sciences.

News, Updates

& Events

Boston Event with Latinos In Bio

🌟 Join us in Boston! 🌟
We’re excited to announce our upcoming event, Building Bridges Between Boston and Biotech in LATAM: Introducing Securitas Bio, an Innovative Venture Studio, happening on October 28th, 2024 from 4:00 pm to 6:30 pm ET at the CIC - Cambridge Mosaic Conf Room.

🔬 This event will feature our CEO & Co-Founder, Matías Vidal, and VP of Medicinal Chemistry, Dr. Mariela Bollini, as they present Securitas Biosciences' vision of advancing biotech innovation across Latin America and the U.S.

👉 Register now to learn more about our cutting-edge work and how we’re building a global biotech ecosystem!

📍 Location: 245 Main Street, Cambridge, MA
🎫 In partnership with Latinos in Bio

Partnership With Hospital Italiano

We are happy to announce our new Co-Development Agreement in Molecular Diagnostics 🤝🔬

On Thursday, July 11th, we celebrated the signing of our first Co-Development Agreement with the Hospital Italiano de Buenos Aires. This collaboration focuses on the co-development of innovative automated molecular diagnostic products based on real-time PCR.
This agreement marks a significant partnership between Securitas Biosciences and the hospital's Diagnostics Department, led by Dr. Hernán García Rivello. The signing, endorsed by Drs. Marcelo Marchetti and Esteban Langlois from the Italian Hospital, and our CEO Matías Vidal, reinforces our commitment to being key players in the growth of the biotechnology ecosystem in Latin America.
We are excited about the potential of this collaboration to advance in in vitro diagnostics through the coordinated efforts with Terra Nova. We look forward to the first molecular diagnostic products resulting from this meaningful partnership. 🌟

Li lingues differe solmen in li grammatica

A wonderful serenity has taken possession of my entire soul, like these sweet mornings of spring which I enjoy with my whole heart. I am alone, and feel the charm of existence in this spot, which was created for the bliss of souls like mine. I am so happy

The languages only differ in their grammar

A wonderful serenity has taken possession of my entire soul, like these sweet mornings of spring which I enjoy with my whole heart. I am alone, and feel the charm of existence in this spot, which was created for the bliss of souls like mine. I am so happy

A wonderful serenity has taken possession

A wonderful serenity has taken possession of my entire soul, like these sweet mornings of spring which I enjoy with my whole heart. I am alone, and feel the charm of existence in this spot, which was created for the bliss of souls like mine. I am so happy

Contact Us